Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

Jiani Wang1 · Qingyuan Zhang3 · Qiao Li1 · Yuxin Mu1 · Jing Jing4 · Huiping Li5 · Wei Li6 · Jingfen Wang7 · Guohua Yu8 · Xian Wang9 · Quchang Ouyang10 · Jing Hao11 · Liang Lu11 · Li Zhou11 · Jin Guan11 · Qing Li1 · Binghe Xu1,2

Accepted: 7 June 2021 / Published online: 1 July 2021 © The Author(s) 2021

Abstract

Background Previous clinical trials have demonstrated that entinostat in combination with exemestane had good tolerability and significant clinical efficacy in patients with advanced hormone receptor positive (HR+) and HER2 negative (HER2−) metastatic breast cancer (MBC) in the USA. However, no clinical trials have been conducted in Chinese populations.

Objective To investigate the safety, pharmacokinetics, and pilot efficacy of entinostat with or without exemestane in Chinese postmenopausal patients with locally advanced or metastatic HR+/HER2− MBC.

Patients and methods Nineteen patients received entinostat for 4 weeks (dose-limiting toxicity (DLT) observation stage) at 3, 5, or 7 mg/week, with a “3+3” dose-escalation design and in combination with exemestane thereafter (extended treatment stage: entinostat, 3 or 5 mg/week; exemestane, 25 mg/day). An additional 21 patients were enrolled to assess the entinostat (5 mg) plus exemestane (25 mg) pharmacokinetic profile and potential efficacy.

Results The peak entinostat serum concentration and area under the curve increased dose proportionally, without significant interaction between entinostat and exemestane. Entinostat was well tolerated at all doses. The most common grade 3/4 adverse effects (AEs) included neutropenia (31.6%) and thrombocytopenia (15.8%). In the DLT observation stage, grade 3/4 AEs accounted for 16.7% in the 5 mg group with one suspicious DLT (G3 ventricular tachycardia) and 33.3% in the 7 mg group.

In the extended treatment stage, 2/16 patients achieved partial response and three patients experienced stable disease (> 12 weeks). The median progression-free survival was 9.41 months for the additional 21 patients, who experienced grade 3/4 AEs of neutropenia (38%), thrombocytopenia (9.5%), anemia (9.5%), and fatigue (9.5%).

Conclusion Entinostat with exemestane showed reasonable safety, tolerability, and encouraging efficacy in Chinese patients with HR+/HER2− MBC. These results support further evaluation in a randomized, double-blind Phase III study with a weekly 5 mg entinostat dose in a Chinese population.

Trial Registration NCT02833155.

Key Points

For Chinese HR+/HER2− metastatic breast cancer patients, 5 mg entinostat with exemestane showed promising efficacy with good tolerability.

With regard to the PK profile, no significant accumulation of entinostat was observed and the PK characteristics of entinostat were not affected by exemestane.

Jiani Wang and Qingyuan Zhang contributed equally as co-first authors.

Qing Li cheryliqing@126.com

Binghe Xu xubinghe@medmail.com

Extended author information available on the last page of the article
1 Introduction

Approximately two-thirds of breast cancer patients belong to the hormone receptor-positive (HR+) subtype, and can be treated with hormonal therapy [1]. However, the 5-year survival rate of patients with advanced disease after recurrence and metastasis is only 25%; eventually all of these patients progress to endocrine-therapy resistance, and approximately 15–20% of patients are resistant to endocrine therapy at the time of initial treatment [2]. Therefore, overcoming resistance to endocrine therapy is an important focus in the effort to improve clinical practice, with implications for the clinical diagnosis and treatment of breast cancer [3]. Breast cancer treatment strategies have been greatly improved in recent years due to the introduction of novel drugs, including CDK4/6 inhibitors [4, 5], anti-PD-1 antibodies [6], and epigenetic modulators [7]. These drugs have provided clinicians with new options for treatments, and they have notable benefits in progression-free survival (PFS) improvement for breast cancer patients [3]. However, despite the wide range of treatment options available, patients with HR+ metastatic breast cancer still have a relatively poor prognosis after inevitable treatment resistance [1].

Epigenetic dysfunction has been reported in breast cancer [8], and targeting epigenetic abnormalities with various modulators has shown anti-cancer efficacy in vivo and in vitro [9–11]. Histone deacetylases (HDACs), which remove the acetyl groups from lysines that have been N-acetylated by histone acetylases, target epigenetic changes in tumors and alter gene regulation; they have recently become important targets for anti-tumor drug design [12]. HDAC inhibitors (HDACIs) can modulate the structure of chromosomes and regulate tumor cell sensitivity to various anti-tumor treatments [13], making HDACIs a current research hotspot in the field of cancer therapy. Multiple HDACIs have shown efficacy for the treatment of solid tumors and hematological malignancies [14].

Entinostat is a benzamide-derivative with promising therapeutic effects in patients with breast cancer. In 2013, it was granted “breakthrough designation” by the US Food and Drug Administration for combination therapy with exemestane for the treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer [15]. Combination therapy with entinostat plus exemestane was generally well tolerated, and prolonged PFS (from 2.3 to 4.3 months) and overall survival (OS; from 19.8 to 28.1 months) of patients with estrogen receptor-positive advanced breast cancer in a signal-finding phase II randomized controlled study (ENCORE 301) [15].

Hence, entinostat in combination with exemestane demonstrated good tolerability and significant clinical efficacy in patients in the USA with advanced HR+ and HER2-negative (HER2−) breast cancer. However, no clinical trials had been conducted in Chinese populations. The aim of the present study was to evaluate the safety, tolerability, and pharmacokinetic profile of entinostat alone and in combination with exemestane in Chinese postmenopausal patients with locally advanced or metastatic HR+ / HER2− metastatic breast cancer.

2 Patients and Methods

2.1 Patient Eligibility

Patients were eligible for enrollment based on the following criteria: (1) postmenopausal women aged ≤ 65 years; (2) estrogen receptor- and/or progesterone receptor-positive (> 1%) breast cancer, confirmed by pathology; (3) previously treated with a non-steroidal aromatase inhibitor (letrozole/anastrozole), with disease progression or relapse afterwards; (4) Eastern Cooperative Oncology Group Performance Status 0–1; (5) a life expectancy of > 3 months; and (6) adequate organ and bone marrow functions. Patients were excluded if they had received prior treatment with an HDACI.

2.2 Study Design

This was a multicenter, open-label, phase I study conducted in China to determine the safety, pharmacokinetics, and efficacy of entinostat in postmenopausal women with HR+ / HER2− advanced breast cancer. The study included two stages. Stage I comprised four treatment cycles (4 weeks per cycle), during which patients received one of three doses (3, 5, or 7 mg) of entinostat orally on a weekly basis. We assessed dose-limiting toxicity (DLT) and tolerability. After stage I, patients could voluntarily participate in Stage II, in which they were given either 3 or 5 mg of entinostat weekly in combination with 25 mg exemestane orally per day, until the occurrence of disease progression (PD), intolerable adverse effects (AEs), or the patient withdrawing consent (see Fig. 1). We enrolled a further 21 patients to investigate the potential interactions between entinostat and exemestane. They received entinostat (5 mg/week) plus exemestane 25 mg/day until PD or intolerable AEs.

The study was approved by the Independent Ethics Committee (EC) of the National Cancer Center/Cancer Hospital, and written informed consent was obtained from all patients before their enrollment in this study. All interventions were performed in accordance with the Declaration of Helsinki guidelines of the International Conference for Harmonization/Good Clinical Practice. The study was registered at ClinicalTrials.gov (NCT 02833155).
2.3 Dose Escalation

The trial followed the traditional “3+3” design. The first stage of the trial consisted of three doses of entinostat (3, 5, and 7 mg). Three patients were administered 3 mg entinostat/week orally for 4 weeks. If no DLT was observed, patients were enrolled in the next dose group. But if one case of DLT occurred, three more patients would be enrolled in the initial dose group. If no more than one case of DLT occurred in this dose group, we escalated to the next dose group. If two patients in one dose group experienced DLT, then this dose was considered the maximum tolerated dose and dose escalation stopped.

According to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0), DLT was defined as an intolerable grade 2 AE that led to discontinuation of treatment or that could not recover to grade 1 during the treatment stage (alopecia excluded), any grade 3 non-hematological AE, or a grade 4 hematological AE.

2.4 Patient Evaluation

Safety evaluations were performed on days 1, 8, 15, and 22 in Stage I, and once every month for Stage II of the treatment. Safety assessments included vital sign measurements, laboratory tests, and electrocardiograms. The efficacy of the treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1. Complete response (CR) or partial response (PR) was confirmed at least 4 weeks after the initial response.

2.5 Pharmacokinetic Analysis

Blood samples for pharmacokinetic analyses of entinostat were collected on days 1 and 22 in both stages. We collected samples 30 min prior to drug administration on days 1, 15, and 22, and at several time points after each dose: 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 120, and 168 h. The plasma concentration of entinostat was measured using a validated liquid chromatography–tandem mass
spectrometry method. The blood samples were stored at −70 °C until testing. Pharmacokinetic analysis was performed using Phoenix WinNonlin version 6.3 (Pharsight, Mountain View, CA, USA). A standard non-compartmental method was used to calculate the peak plasma concentration (C\text{max}), the time to C\text{max} (t\text{max}), the total area under the concentration-time curve (AUC\text{0-∞}), and the elimination half-life (t\text{1/2}).

3 Results

3.1 Patient Characteristics

From August 2016 to July 2018, we enrolled 19 patients, all of whom participated in Stage I of the treatment plan, and 16 of whom participated in Stage II. Baseline characteristics of these enrolled patients are summarized in Table 1. To investigate the potential interaction between entinostat and exemestane, we enrolled an additional 21 patients from May 2018 to July 2018 who received 5 mg entinostat once per week plus 25 mg exemestane daily until PD or intolerable AE.

3.2 Entinostat Dose Escalation

In Stage I, no patients experienced a DLT in any of the dose groups. In Stage II, one patient in the 5 mg entinostat group (1/14, 7.1%) had CTCAE grade 3 arrhythmia, and required medical care. Median tolerance limit (MLT) was not achieved throughout the trial.

3.3 Safety

Nineteen patients were enrolled in Stage I of the treatment plan, in which entinostat was administered as a monotherapy (four in the 3 mg group, 12 in the 5 mg group, and three in the 7 mg group). All 19 patients experienced entinostat-related AEs (100%), of whom 16 patients continued to Stage II of the treatment plan (two in the 3 mg entinostat plus exemestane group and 14 in the 5 mg entinostat plus exemestane group). Three patients in the 7 mg group in Stage I were transferred to the 5 mg group in Stage II due to safety concerns. The AEs that occurred in two or more patients are shown in Table 2. In Stage I, no CTCAE grade 3 AE occurred in the 3 mg/week group. Two subjects in the 5 mg/week group had four cases of CTCAE grade 3 AE. One subject in the 7 mg/week group experienced a CTCAE grade 3 AE. In prolonged Stage II, no grade 3 AE occurred in the 3 mg/week group. Ten subjects in the 5 mg/week group experienced 38 CTCAE grade ≥ 3 AEs.

We also assessed the safety of the regimen in the 21 patients who provided blood samples for pharmacokinetic analysis. Those patients experienced grade 3/4 AEs as follows: neutropenia (38%), thrombocytopenia (9.5%), anemia (9.5%), and fatigue (9.5%).

In the DLT observation stage, one suspicious DLT (G3 ventricular tachycardia) occurred in the 5 mg group. Subject 0105 did not have coronary heart disease or other heart-related basic diseases before the clinical trial. The baseline screening ECG indicated sinus rhythm and normal outcome. In the clinical study, palpitation symptoms were closely observed during treatment. The patient's 24-h dynamic electrocardiogram indicated sinus tachycardia. The cardiologist preliminarily made a diagnosis of "ventricular tachycardia"

| Characteristic | Entinostat dose (mg/day) cohorts | Stage I (n = 19) | Stage II (n = 16) |
|----------------|---------------------------------|-----------------|------------------|
|                | 3 mg | 5 mg | 7 mg | 3 mg | 5 mg |
| Median age, years (range) | 53.5 (41–60) | 53.0 (40–65) | 53.0 (35–56) | 53.5 (41–60) | 53.0 (40–65) |
| ECOG 0 | 4 | 12 | 3 | 2 | 13 |
| ECOG 1 | 0 | 0 | 0 | 0 | 1 |
| HR ER+ | 4 | 12 | 3 | 2 | 14 |
| HR PR+ | 1 | 11 | 2 | 1 | 12 |
| Prior treatment Chemotherapy | 4 | 12 | 3 | 2 | 14 |
| Prior treatment Hormone therapy | 4 | 12 | 3 | 2 | 14 |
| Prior treatment Radiotherapy | 4 | 7 | 3 | 2 | 9 |

ECOG Eastern Cooperative Oncology Group, ER+ estrogen receptor-positive, PR+ progesterone receptor-positive
and gave her the appropriate medication, which met the termination criterion of "grade 3 ventricular arrhythmia." The patient was followed up for 35 days after withdrawal, and the symptoms of conscious palpitation were relieved. On 10 February 2017 (the 41st day after the last medication), no ventricular arrhythmia was observed in the 24-h dynamic electrocardiogram.

### 3.4 Efficacy

Of the 16 patients who completed the treatment plan (Stages I and II), only 14 patients were evaluated for therapeutic efficacy (Table 3). Of these 14 patients, none achieved CR. Two patients in the 5 mg group in both stages achieved PR. Three patients from all three treatment groups experienced stable disease. Nine patients from the three groups experienced PD. The overall response rate (ORR), defined as the combined rates of patients who achieved CR and PR, was 2/14 (14.3%) (Fig. 2A). Survival analysis showed that the PFS of the enrolled patients, counted from the date of the first dose of entinostat, was 85.5 days in the 5 mg group (95% confidence interval (CI): 78–201), and 90 days in the 7 mg→5 mg cohort (95% CI: 85–426). None of the patients in the 3 mg group experienced PR.

For the 21 patients enrolled to assess the pharmacokinetic profile of entinostat (5 mg) administered in combination with exemestane (25 mg), the ORR (CR+PR) was 2/14 (14.3%) (Fig. 2A). Survival analysis showed that the PFS of the enrolled patients, counted from the date of the first dose of entinostat, was 85.5 days in the 5 mg group (95% confidence interval (CI): 78–201), and 90 days in the 7 mg→5 mg cohort (95% CI: 85–426). None of the patients in the 3 mg group experienced PR.

Of the 16 patients who completed the treatment plan (Stages I and II), only 14 patients were evaluated for therapeutic efficacy (Table 3). Of these 14 patients, none achieved CR. Two patients in the 5 mg group in both stages achieved PR. Three patients from all three treatment groups experienced stable disease. Nine patients from the three groups experienced PD. The overall response rate (ORR), defined as the combined rates of patients who achieved CR and PR, was 2/14 (14.3%) (Fig. 2A). Survival analysis showed that the PFS of the enrolled patients, counted from the date of the first dose of entinostat, was 85.5 days in the 5 mg group (95% confidence interval (CI): 78–201), and 90 days in the 7 mg→5 mg cohort (95% CI: 85–426). None of the patients in the 3 mg group experienced PR.

For the 21 patients enrolled to assess the pharmacokinetic profile of entinostat (5 mg) administered in combination with exemestane (25 mg), the ORR (CR+PR) was 2/14 (14.3%) (Fig. 2A). Survival analysis showed that the PFS of the enrolled patients, counted from the date of the first dose of entinostat, was 85.5 days in the 5 mg group (95% confidence interval (CI): 78–201), and 90 days in the 7 mg→5 mg cohort (95% CI: 85–426). None of the patients in the 3 mg group experienced PR.

### 3.5 Pharmacokinetics

Blood samples from all 19 patients in Stage I were collected for analysis of the pharmacokinetics of entinostat. The values of the pharmacokinetic indexes are shown in Table 4A and B. Regression analysis showed a linear relationship between AUC_{0-168} and entinostat dose, but the relationship

---

**Table 2** Entinostat-related adverse events (AEs) of all grades in the two stages

| AE                | Stage I |        |        |        |        | Stage II |        |        |        |
|-------------------|---------|--------|--------|--------|--------|---------|--------|--------|--------|
|                   | 3 mg    | 5 mg   | 7 mg   | 3 mg   | 5 mg   |
| Leukopenia        | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 7 (58.3)|
| Neutropenia       | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 4 (33.3)|
| Anemia            | 0 (0)   | 1 (6.7)| 0 (0)  | 2 (100)| 10 (71.4)|
| Thrombocytopenia  | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| AKP elevation     | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| ALT elevation     | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| AST elevation     | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| α-HBDH elevation  | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| γ-GT elevation    | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Fatigue           | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Chest pain        | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Nausea            | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Abdominal pain    | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Back pain         | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Palpitation       | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Headache          | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Flatulence        | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Serum phosphate decrease | 0 (0) | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Creatinine increase | 0 (0) | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Creatine increase | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Serum albumin decrease | 0 (0) | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Serum Ca²⁺ decrease | 0 (0) | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Serum Na⁺ decrease | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Serum urea increase | 0 (0) | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| LDH increase      | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Hypoaalbuminemia  | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Hypoproteinemina  | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Hypocalcemia      | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Hypokalemia       | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Diarrhea          | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|
| Limb pain         | 0 (0)   | 0 (0)  | 0 (0)  | 3 (75) | 2 (16.7)|

AKP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, α-HBDH α-hydroxybutyrate dehydrogenase, γ-GT γ-glutamyl transferase, LDH lactate dehydrogenase

**Table 3** Clinical responses

| Entinostat dose | Response |
|-----------------|---------|
| 3 mg (n = 2)    | CR 0    |
| 5 mg (n = 9)    | CR 0    |
| 7 mg→5 mg (n = 3) | CR 0    |

CR complete response, PR partial response, SD stable disease, PD disease progression

Blood samples from all 19 patients in Stage I were collected for analysis of the pharmacokinetics of entinostat. The values of the pharmacokinetic indexes are shown in Table 4A and B. Regression analysis showed a linear relationship between AUC_{0-168} and entinostat dose, but the relationship

---

△ Adis
between $C_{\text{max}}$ and dose was unclear due to the relatively small sample size.

The PK profile of the additional 21 subjects suggested that there was no significant interaction between entinostat and exemestane (see Table 4C).

### 4 Discussion

The purpose of this phase I trial was to assess the safety and pharmacokinetics of entinostat in Chinese patients with locally recurrent/metastatic breast cancer. We chose the dosage of entinostat based on the data collected from previous Phase I and Phase II trials of entinostat performed outside China [15, 16], i.e., oral administration of 3, 5, and 7 mg entinostat once weekly for Stage I.

In the three dose groups of this study, entinostat-related adverse events were mostly mild or moderate, and no DLT events occurred during the DLT observation period. Subject 0105 in the 5 mg/week group had adverse events during the extended treatment period, classified as grade 3 ventricular arrhythmia (MedDRA code as "ventricular arrhythmia"), which was determined by the investigator to be possibly related to the study drugs. The adverse events were considered to have appeared during Stage I and worsened to level 3 during Stage II, which was classified as DLT. The remaining subjects tolerated treatment well without any serious AEs related to the study drugs. Most of the subjects’ symptoms were self-relieved or no longer appeared, without affecting the follow-up treatment process.

Since only one DLT occurred (arrhythmia) in the 5 mg group, and the patient’s symptoms were relieved after symptomatic treatment, we concluded that the patients showed good tolerance to these dosages. However, based on the results of the dose-escalation phase, and the dose of entinostat used in the Phase III trial in the USA, we changed the dose group from 7 mg in Stage I to 5 mg in Stage II.

The most common AEs observed in this trial were hematological toxicities, including leukopenia, neutropenia, thrombocytopenia, and anemia. This differed from what had been observed in previous clinical trials conducted in the USA, in which the most common AEs were nausea, vomiting, and fatigue [15, 16]. Interestingly, the AE spectrum observed in this trial was similar to that observed for another HDACI, chidamide, in Chinese patients with advanced breast cancer [17]. We believe that these distinct AE spectra may be attributable to the genetic characteristics of the different ethnic groups. Although entinostat is associated with more toxicity than hormonal therapy, the level of toxicity is considered acceptable for this patient population.

We also compared the safety profile and efficacy of entinostat with those of an HDACI that has been approved in China for the treatment of breast cancer, chidamide, using the published data from its crucial, market-launching Phase III trial (NCT02482753) [17]. In combination with exemestane, chidamide treatment yielded a median PFS of 7.4 months, with neutropenia in 51% and thrombocytopenia in 28% of patients. In this trial, entinostat in combination with exemestane yielded a longer median PFS (9.41 months), and lower occurrence rates of neutropenia and thrombocytopenia (33% and 10%, respectively).

There was no significant difference in major pharmacokinetic parameters between the breast cancer subjects on day 1 and day 22 after entinostat administration. The median $T_{\text{max}}$ of each dose group on day 1 and day 22 was about 0.5 h; the median $T_{1/2}$ was between 38.3 and 65.3 h; the median $C_{\text{max}}$ was 44.5–150.0 ng/mL; the median AUC$_{0-168h}$ was 451–1180 h·ng/mL, and the AUC$_{0-168h}$ and $C_{\text{max}}$ in the dosages range of 3–7 mg have a linear trend, but the linear relationship is not clear yet. The primary cause was due to the small amount of samples, and high individual variation of tumor patients in the 3 and 5 mg dose groups.
Fig. 3 Potential efficacy of additional 21 patients enrolled to assess the entinostat (5 mg) plus exemestane (25 mg) pharmacokinetic profile

Table 4 Pharmacokinetic index values for entinostat and exemestane

(A) Compound Day Dose Cohort $C_{max}$ $t_{max}$ AUC inf $t_{1/2}$ CL/F (mg) N (ng/mL) (h) (h·ng/mL) (h) L/h

Entinostat
1 3 3* 49.2 ± 8.38 0.50 (0.25, 0.53) 572 ± 122 38.3 (14.3, 218) 5.42 ± 1.26
5 12 101 ± 62.1 0.50 (0.25, 7.92) 1070 ± 364 51.7 (33.8, 156) 5.08 ± 1.31
7 3 154 ± 39.2 0.55 (0.50, 1.0) 1380 ± 206 48.1 (42.5, 87.6) 5.15 ± 0.76

(B) Compound Day Dose Cohort $C_{max}$ $t_{max}$ AUC inf $t_{1/2}$ CL/F AR (mg) N (ng/mL) (h) (h·ng/mL) (h) L/h

Entinostat
22 3 3* 55.7 ± 38.2 0.47 (0.28, 7.92) 609 ± 44.3 65.3 (61.2, 66.7) 4.94 ± 0.36 1.30 ± 0.19
5 12 107 ± 63.2 0.50 (0.25, 8.00) 1310 ± 349 61.9 (40.2, 195) 4.00 ± 0.85 1.46 ± 0.19
7 3 122 ± 76.1 0.50 (0.23, 2.00) 1650 ± 452 56.2 (53.6, 127) 4.45 ± 1.14 1.38 ± 0.12

(C) Compound Stage mg/dose Cohort $t_{1/2}$ $t_{max}$ $C_{max}$ AUC0-4 (h) (h) (ng/mL) (h·ng/mL)

Exemestane
Lead in 25 mg 21 6.24 (1.87, 14.0) 1.02 (0.50, 8.03) 17.0 (5.66, 70.5) 54.6 (27.5, 128)
Combo 25 mg 21 5.68 (2.22, 7.98) 3.95 (1.95, 12.00) 13.0 (5.06, 57.4) 58.8 (27.1, 109)

$AUC$ area under the plasma concentration-time curve, $CL/F$ oral clearance, $C_{max}$ maximum plasma concentration, $t_{1/2}$ half-life

$t_{max}$ and $t_{1/2}$ are shown as median (Min., Max.), and other parameters are shown as mean ± SD

COVANCE-EOC103 China Ph1 PK report;

*1 subject with an AUC extrapolated percentage > 30%

The data are included in the descriptive statistics
should also be considered. On the 22nd day after entinostat administration, the drug had basically reached steady state [18]. The mean accumulation ratio (AR_AUC0–168h) of entinostat in breast cancer subjects was between 1.30 and 1.46 after four doses of the drug, indicating that entinostat had no significant accumulation in breast cancer subjects [19]. The single-dose administration in the Phase I clinical study in China was similar to the plasma concentration and exposure of entinostat combination with exemestane study, and the pharmacokinetic characteristics of entinostat were not affected by exemestane.

4.1 Limitations

The limitations of this study include the lack of tissue and serum collection prior to and during the study. Collection of tissue and serum samples in future studies will facilitate the observation of changes in lysine acetylation, which will further improve treatment strategies and patient selection. Indeed, the association between HDAC inhibition and entinostat-induced acetylation of lysine should be demonstrated in planned confirmatory studies. An on-going randomized, double-blind Phase III trial in Chinese metastatic breast cancer patients (NCT03538171) might provide further insight into the efficacy of entinostat plus exemestane combination therapy.

4.2 Conclusion

In conclusion, we found that entinostat in combination with exemestane was well tolerated in this cohort of Chinese patients and showed encouraging efficacy in reducing tumor volumes. Based on our results, we recommend administration of 5 mg entinostat once weekly in combination with exemestane as a promising treatment option for patients with advanced breast cancer.

Acknowledgements We thank the participants in this study and gratefully acknowledge the collaboration of all investigators for their contributions. We thank Editage language for editorial assistance. We thank Xueying Wu from EOC Pharmaceutical CO for assisting us with the data analysis and the linguistic review. This study (ClinicalTrials.gov NCT02833155) was sponsored by EOC Pharmaceutical CO, National Key Research and Development Program of China (No. 2018YFC1312101), and Chinese Academy of Medical Science Initiative for Innovative Medicine (No. CAMS-2016-I2M-1-010).

Declarations

Funding This work was supported by the National Key Research and Development Program of China (No. 2018YFC1312101) and Chinese Academy of Medical Science Initiative for Innovative Medicine (No. CAMS-2016-I2M-1-010).

Conflicts of interest Jiani Wang, Qingyuan Zhang, Qiao Li, Yuxin Mu, Jing Jing, Huiping Li, Wei Li, Jingfen Wang, Guohua Yu, Xian Wang, Quchang Ouyang, Jing Hao, Liang Lu, Li Zhou, Jin Guan, Qing Li, and Binghe Xu declare that they have no conflicts of interest that might be relevant to the contents of this article.

Ethics approval This clinical trial received EC approval.

Consent of participate This clinical trial obtained informed consent from all participated subjects.

Consent for publication Not applicable.

Availability of data and material The datasets generated and analyzed during the current study are not publicly available due the confidential requirements of the new product, but are available from the corresponding author on reasonable request.

Code availability Not applicable.

Authors’ contributions Conception and design: Q. Li and B. Xu. Development of methodology: Q. Li, J. Wang, Q. Li, B. Xu. Acquisition of data (acquired and managed patients, provided facilities, etc.): J. Wang, Q. Zhang, Q. Li, Y. Mu, J. Jing, H. Li, W. Li, J. Wang, G. Yu, X. Wang, Q. Ouyang, Q. Li, and B. Xu. Analysis and interpretation of data (e.g., statistical analysis, computational analysis): L. Lu, L. Zhou, J. Guan, J. Hao, and J. Wang. Writing, review, and/or revision of the manuscript: J. Wang, Q. Li, and B. Xu. Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Wang, Q. Zhang, Q. Li, and Y. Mu. Study supervision: Q. Li and B. Xu.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Flaum LE, Gradishar WJ. Advances in endocrine therapy for postmenopausal metastatic breast cancer. Cancer Treat Res. 2018;173:141–54. https://doi.org/10.1007/978-3-319-70197-4_9.

2. Radhi S. Molecular changes during breast cancer and mechanisms of endocrine therapy resistance. Prog Mol Biol Transl Sci. 2016;144:539–62. https://doi.org/10.1016/bs.pmbts.2016.09.009.

3. Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015;12(9):541–52. https://doi.org/10.1038/nrclinonc.2015.99.

4. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36. https://doi.org/10.1056/NEJMoa1607303.

5. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Palunich-Shimon S, et al. Ribociclib as first-line
therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. https://doi.org/10.1056/NEJMoA1609709.

6. Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. https://doi.org/10.1056/NEJMoa1910549.

7. Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, et al. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res. 2017;37(1):35–46. https://doi.org/10.21873/anticancerres.11286.

8. Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol. 2018;51:22–35. https://doi.org/10.1016/j.semcancer.2018.01.007.

9. de Almeida BP, Apolonio JD, Binnie A, Castelo-Branco P. Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer. 2019;19(1):219. https://doi.org/10.1186/s12885-019-5403-0.

10. Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AT, Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:7. https://doi.org/10.3390/ijms18071414.

11. You D, Richardson JR, Aleksovska LM. Epigenetic regulation of multidrug resistance protein 1 and breast cancer resistance protein transporters by histone deacetylation inhibition. Drug Metab Dispos. 2020;48(6):459–80. https://doi.org/10.1124/dmd.19.089953.

12. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:7. https://doi.org/10.3390/ijms18071414.

13. Qu K, Zaba LC, Satpathy AT, Giresi PG, Li R, Jin Y, et al. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell. 2017;32(1):27–41. https://doi.org/10.1016/j.ccell.2017.05.008.

14. McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:459–80. https://doi.org/10.1016/bs.acr.2018.02.006.

15. Yardley DA, Ismail-Khan RR, Melichar B, Lichiniser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–35. https://doi.org/10.1200/jco.2012.43.7251.

16. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepal JB, Ye J, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23(17):3912–22. https://doi.org/10.1200/jco.2005.02.188.

17. Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(6):806–15. https://doi.org/10.1016/s1470-2045(19)30164-0.

18. Derendorf H, Schmidt S. Rowland and Tozer’s clinical pharmacokinetics and pharmacodynamics: concepts and applications. Chapter, vol 11. 2020. p. 176–179.

19. Liu KX. Clinical pharmacokinetics evaluation of new drugs. Clin Pharmacokinet. 2020;18:280-282.

Authors and Affiliations

Jiani Wang¹ · Qingyuan Zhang³ · Qiao Li¹ · Yuxin Mu¹ · Jing Jing⁴ · Huiping Li⁵ · Wei Li⁶ · Jingfen Wang⁷ · Guohua Yu⁸ · Xian Wang⁹ · Quchang Ouyang¹⁰ · Jing Hao¹¹ · Liang Lu¹¹ · Li Zhou¹¹ · Jin Guan¹¹ · Qing Li¹ · Binghe Xu¹,²

¹ Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuananli, Chaoyang District, Beijing 100021, China

² State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

³ Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang, China

⁴ Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China

⁵ Department of Breast Oncology, Peking University Cancer Hospital and Institute, No. 52, Beijing 100142, China

⁶ Department of Medical Oncology, The First Bethune Hospital of Jilin University, Changchun 130021, Jilin, China

⁷ Oncology Division of Breast Cancer, Linyi Cancer Hospital, Linyi 276000, Shandong, China

⁸ Department of Breast Oncology, Weifang People’s Hospital, Weifang 261000, Shandong, China

⁹ Department of Breast Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang, China

¹⁰ Oncology Division of Breast Cancer, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China

¹¹ Taizhou EOC Pharma Co., Ltd., Taizhou 225300, Jiangsu, China

△ Adis